Travere Therapeutics Files 8-K on Financial Results

TL;DR

**Travere Therapeutics just filed an 8-K on their financial results, details pending.**

AI Summary

Travere Therapeutics, Inc. filed an 8-K on February 15, 2024, reporting on Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial Statements and Exhibits. This filing indicates the company is disclosing its financial performance, though specific details are not provided in this excerpt. The company, with Commission File Number 001-36257, is incorporated in Delaware and has its business address in San Diego, CA.

Why It Matters

This 8-K signals that Travere Therapeutics is releasing its financial performance, which is crucial for investors to assess the company's health and future prospects. The specific details, once available, will inform market reactions and investment decisions.

Risk Assessment

Risk Level: medium — The filing indicates a disclosure of financial results, which can introduce volatility depending on the reported performance, but the specific impact is unknown without the full content.

Key Players & Entities

• Travere Therapeutics, Inc. (company) — registrant
• Retrophin, Inc. (company) — former name
• Desert Gateway, Inc. (company) — former name
• Delaware (location) — state of incorporation
• San Diego (location) — business address city
• CA (location) — business address state
• February 15, 2024 (date) — date of report
• 001-36257 (identifier) — Commission File Number
• 27-4842691 (identifier) — I.R.S. Employer Identification No.
• 888-969-7879 (phone_number) — business phone

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TVTX The Nasdaq Global Marke

Filing Documents

• tvtx-20240215.htm (8-K) — 33KB
• aex991_2023q4x10xkearnings.htm (EX-99.1) — 181KB
• imagea.jpg (GRAPHIC) — 9KB
• 0001438533-24-000003.txt ( ) — 374KB
• tvtx-20240215.xsd (EX-101.SCH) — 2KB
• tvtx-20240215_lab.xml (EX-101.LAB) — 25KB
• tvtx-20240215_pre.xml (EX-101.PRE) — 13KB
• tvtx-20240215_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 15, 2024, Travere Therapeutics, Inc. (the "Company") issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2023. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Travere Therapeutics, Inc. dated February 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRAVERE THERAPEUTICS, INC. Dated: February 15, 2024 By: /s/ Eric Dube Name: Eric Dube Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR